Effect of High-dose Telmisartan on the Prevention of Recurrent Atrial Fibrillation in Hypertensive Patients

about

Effect of High-dose Telmisartan on the Prevention of Recurrent Atrial Fibrillation in Hypertensive Patients

Item

http://www.wikidata.org/entity/Q37114614

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 October 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effect of High-dose Telmisarta ...... ation in Hypertensive Patients

@en

Effect of High-dose Telmisarta ...... tion in Hypertensive Patients.

@nl

type

Item

label

Effect of High-dose Telmisarta ...... ation in Hypertensive Patients

@en

Effect of High-dose Telmisarta ...... tion in Hypertensive Patients.

@nl

prefLabel

Effect of High-dose Telmisarta ...... ation in Hypertensive Patients

@en

Effect of High-dose Telmisarta ...... tion in Hypertensive Patients.

@nl

P1476

Effect of High-dose Telmisarta ...... ation in Hypertensive Patients

@en

P2093

Harumizu Sakurada

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Fujii

http://www.w3.org/2001/XMLSchema#string

Kensuke Ihara

http://www.w3.org/2001/XMLSchema#string

Masayasu Hiraoka

http://www.w3.org/2001/XMLSchema#string

Mitsuaki Isobe

http://www.w3.org/2001/XMLSchema#string

Mitsuhiro Nishizaki

http://www.w3.org/2001/XMLSchema#string

Noriyoshi Yamawake

http://www.w3.org/2001/XMLSchema#string

Shingo Maeda

http://www.w3.org/2001/XMLSchema#string

Tadashi Murai

http://www.w3.org/2001/XMLSchema#string

Takashi Ashikaga

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Telmisartan, ramipril, or both in patients at high risk for vascular events.

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.

Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation.

Venice Chart international consensus document on atrial fibrillation ablation.

Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study.

Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation.

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.

P304

289

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4022/JAFIB.289

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28496669

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation

P932

4955903

http://www.w3.org/2001/XMLSchema#string